Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With ISN/RPS Class III or IV Lupus Nephritis

NCT00282347 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT00282347
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00282347 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With ISN/RPS Class III or IV Lupus Nephritis
Lead sponsor
Genentech, Inc.
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2006
Completion date
January 31, 2013
Enrollment
144 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

lupus nephritis